JP2012505238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505238A5 JP2012505238A5 JP2011531180A JP2011531180A JP2012505238A5 JP 2012505238 A5 JP2012505238 A5 JP 2012505238A5 JP 2011531180 A JP2011531180 A JP 2011531180A JP 2011531180 A JP2011531180 A JP 2011531180A JP 2012505238 A5 JP2012505238 A5 JP 2012505238A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- disorders
- compound
- bond
- gaba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 78
- 150000001875 compounds Chemical class 0.000 claims description 63
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 48
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 19
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 12
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 11
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 11
- 208000019022 Mood disease Diseases 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 9
- 230000001430 anti-depressive effect Effects 0.000 claims description 9
- 239000000935 antidepressant agent Substances 0.000 claims description 9
- 229940005513 antidepressants Drugs 0.000 claims description 9
- 229960001233 pregabalin Drugs 0.000 claims description 8
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 8
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 229960000794 baclofen Drugs 0.000 claims description 6
- 229960002870 gabapentin Drugs 0.000 claims description 6
- 208000027753 pain disease Diseases 0.000 claims description 6
- 229960005318 vigabatrin Drugs 0.000 claims description 6
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 206010033864 Paranoia Diseases 0.000 claims description 5
- 208000027099 Paranoid disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
- 208000016620 Tourette disease Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000018459 dissociative disease Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 150000002466 imines Chemical class 0.000 claims description 5
- 206010022437 insomnia Diseases 0.000 claims description 5
- 208000022821 personality disease Diseases 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 125000000626 sulfinic acid group Chemical group 0.000 claims description 5
- 206010042772 syncope Diseases 0.000 claims description 5
- -1 opioid Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 8
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001773 anti-convulsant effect Effects 0.000 description 4
- 230000000648 anti-parkinson Effects 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 239000000939 antiparkinson agent Substances 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 208000017194 Affective disease Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10380008P | 2008-10-08 | 2008-10-08 | |
| US61/103,800 | 2008-10-08 | ||
| PCT/US2009/060058 WO2010042759A2 (en) | 2008-10-08 | 2009-10-08 | Gaba conjugates and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032554A Division JP6167123B2 (ja) | 2008-10-08 | 2015-02-23 | Ｇａｂａコンジュゲートおよびそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505238A JP2012505238A (ja) | 2012-03-01 |
| JP2012505238A5 true JP2012505238A5 (enExample) | 2012-05-24 |
Family
ID=42101220
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531180A Withdrawn JP2012505238A (ja) | 2008-10-08 | 2009-10-08 | Ｇａｂａコンジュゲートおよびそれらの使用方法 |
| JP2015032554A Active JP6167123B2 (ja) | 2008-10-08 | 2015-02-23 | Ｇａｂａコンジュゲートおよびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032554A Active JP6167123B2 (ja) | 2008-10-08 | 2015-02-23 | Ｇａｂａコンジュゲートおよびそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8268887B2 (enExample) |
| EP (2) | EP3075722A1 (enExample) |
| JP (2) | JP2012505238A (enExample) |
| KR (1) | KR101810246B1 (enExample) |
| CN (2) | CN102216257B (enExample) |
| AU (1) | AU2009302241B2 (enExample) |
| BR (1) | BRPI0919811B1 (enExample) |
| CA (1) | CA2740087C (enExample) |
| ES (1) | ES2589915T3 (enExample) |
| HK (1) | HK1220970A1 (enExample) |
| WO (1) | WO2010042759A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| AU2010223045A1 (en) * | 2009-03-12 | 2011-11-03 | Luitpold Pharmaceuticals, Inc. | GABA-linked anthracycline-lipid conjugates |
| CA2759251C (en) | 2009-04-23 | 2017-01-03 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
| WO2012025213A2 (en) * | 2010-08-23 | 2012-03-01 | Grünenthal GmbH | Novel therapeutic compounds |
| BR112013020620A2 (pt) * | 2011-02-14 | 2016-10-04 | Concert Pharmaceuticals Inc | análogos de ácido 4-hidroxibutírico |
| WO2012161798A1 (en) * | 2011-02-25 | 2012-11-29 | Catabasis Pharmaceuticals, Inc. | Fatty acid gamma aminobutyric acid (gaba) conjugates and their uses |
| CN103193669B (zh) * | 2013-02-27 | 2014-10-01 | 南京医科大学 | nNOS-Capon解偶联化合物及其制备方法和应用 |
| WO2015184542A1 (en) * | 2014-06-02 | 2015-12-10 | Ketogen Inc. | Compounds for the treatment of seizures and other central nervous system disorders and conditions |
| CA3045004A1 (en) * | 2015-12-16 | 2017-06-22 | Achelios Therapeutics, Inc. | Methods and compositions for treating peripheral neuropathy |
| CN105777586A (zh) * | 2016-04-14 | 2016-07-20 | 安徽省逸欣铭医药科技有限公司 | S（+）氨己烯酸酯衍生物及其制备方法和用途 |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2018075730A1 (en) * | 2016-10-21 | 2018-04-26 | Axim Biotechnologies, Inc. | Suppositories comprising cannabinoids |
| DK3698791T3 (da) * | 2017-02-02 | 2024-01-15 | Otolanum Ag | Intranasal sammensætning, der omfatter betahistin |
| JP7441181B2 (ja) * | 2018-05-14 | 2024-02-29 | エックスジーン ファーマシューティカル インク． | ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態 |
| CN108863873A (zh) * | 2018-06-26 | 2018-11-23 | 台州学院 | 一种硫烯丙基碳酸酯类化合物及其制备方法 |
| KR102107304B1 (ko) * | 2018-08-24 | 2020-05-06 | (주)엠앤씨생명과학 | 천연 리포좀, 그 제조방법 및 이를 포함하는 식품 조성물 |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| WO2023019154A1 (en) * | 2021-08-11 | 2023-02-16 | Tris Pharma, Inc. | Oxybate polyethylene glycol prodrugs |
| CN114452256A (zh) * | 2021-12-31 | 2022-05-10 | 浙江大学 | 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2023215323A1 (en) * | 2022-05-02 | 2023-11-09 | The Regents Of The University Of California | Intranasal baclofen |
| CN117843589A (zh) * | 2022-10-09 | 2024-04-09 | 天津谷堆生物医药科技有限公司 | 取代3-氟苯丙酸酯类化合物及其制备方法、药物组合及用途 |
| CN120530092A (zh) * | 2022-11-24 | 2025-08-22 | 昌郁医药公司 | 萘普生和普瑞巴林1-(酰氧基)-烷基氨基甲酸酯药物缀合物纯化方法 |
| WO2024196851A1 (en) * | 2023-03-17 | 2024-09-26 | Northwestern University | Bicyclic compounds as inactivators of oat and gaba-at |
| CN116585298A (zh) * | 2023-06-30 | 2023-08-15 | 江苏海洋大学 | 一种偶联药物及其组合物和应用 |
| WO2025250613A1 (en) * | 2024-05-29 | 2025-12-04 | Xgene Pharmaceutical Inc. | Method of treating pain using topical naproxen and pregabalin conjugate formulations |
| CN118902084A (zh) * | 2024-08-08 | 2024-11-08 | 天津华德益宝生命科学研发有限公司 | 一种美容养颜含γ-氨基丁酸的海洋特膳食品 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US404175A (en) | 1889-05-28 | O g o o o | ||
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| IL67445A (en) * | 1982-12-09 | 1985-11-29 | Teva Pharma | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| DE3475065D1 (en) | 1983-06-23 | 1988-12-15 | Merck & Co Inc | (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| DE3769676D1 (de) * | 1986-03-14 | 1991-06-06 | Fujisawa Pharmaceutical Co | Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung. |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| WO1992009560A1 (en) | 1990-11-27 | 1992-06-11 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| DK0641330T3 (da) | 1992-05-20 | 2001-12-03 | Univ Northwestern | Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling |
| US5376359A (en) * | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| DE69712877T2 (de) | 1996-02-07 | 2002-11-14 | Warner-Lambert Co., Morris Plains | Zyklischaminosäure als pharmazeutische mittel |
| EA001214B1 (ru) | 1996-03-14 | 2000-12-25 | Варнер-Ламберт Компани | Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества |
| DK0888286T3 (da) | 1996-03-14 | 2002-02-18 | Warner Lambert Co | Nye substituerede cykliske aminosyrer som farmaceutiske midler |
| NZ334898A (en) | 1996-10-23 | 2000-09-29 | Warner Lambert Co | Substituted gamma aminobutyric acids as pharamceutical agents |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| WO1999012537A1 (en) | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
| NZ503963A (en) | 1997-12-16 | 2002-09-27 | Warner Lambert Co | 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders |
| WO1999031074A2 (en) | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders |
| CN1279667A (zh) | 1997-12-16 | 2001-01-10 | 沃尼尔·朗伯公司 | 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
| JP2002516312A (ja) | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 |
| GB9819926D0 (en) | 1998-09-14 | 1998-11-04 | Mead Corp | A tray container and blank |
| NZ510145A (en) | 1998-09-14 | 2003-02-28 | Warner Lambert Co | Branched alkyl pyrrolidine-3-carboxylic acids useful in protective action against cardiazole cramp and cerebral conditions such as epilepsy, hypokinesia and cranial traumas |
| WO2000031020A1 (en) | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| US6451857B1 (en) | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| NZ522480A (en) | 2000-06-26 | 2005-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
| NZ529661A (en) | 2001-06-05 | 2006-03-31 | Control Delivery Systems | Sustained-release analgesic compounds |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ES2399977T3 (es) * | 2001-09-27 | 2013-04-04 | Ramot At Tel Aviv University Ltd. | Conjugado de perfenazina o flufenazina con ácidos carboxílicos |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| ITMI20022658A1 (it) * | 2002-12-17 | 2004-06-18 | Nicox Sa | Farmaci per il dolore cronico. |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| CN101232868A (zh) | 2005-04-19 | 2008-07-30 | 阿尔扎公司 | 曲马多和加巴喷丁的控释递药剂型 |
| EP2272537A3 (en) * | 2005-06-07 | 2014-10-22 | Ramot at Tel-Aviv University Ltd. | Salts of conjugated psychotropic drugs and processes of preparing same |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| MXPA05011735A (es) | 2005-11-01 | 2007-04-30 | Leopoldo Espinosa Abdala | Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico. |
| EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| WO2008010223A2 (en) * | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| WO2008011016A2 (en) | 2006-07-18 | 2008-01-24 | Dynogen Pharmaceuticals, Inc. | Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists |
| WO2008009663A1 (en) | 2006-07-19 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Treatment of pain |
| CA2672044A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| ES2589915T3 (es) | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
-
2009
- 2009-10-08 ES ES09819911.0T patent/ES2589915T3/es active Active
- 2009-10-08 BR BRPI0919811-3A patent/BRPI0919811B1/pt active IP Right Grant
- 2009-10-08 US US12/576,136 patent/US8268887B2/en active Active
- 2009-10-08 CN CN200980145237.6A patent/CN102216257B/zh active Active
- 2009-10-08 CA CA2740087A patent/CA2740087C/en active Active
- 2009-10-08 KR KR1020117010420A patent/KR101810246B1/ko active Active
- 2009-10-08 CN CN201510667046.3A patent/CN105330603A/zh active Pending
- 2009-10-08 EP EP16159660.6A patent/EP3075722A1/en not_active Withdrawn
- 2009-10-08 EP EP09819911.0A patent/EP2344447B1/en active Active
- 2009-10-08 AU AU2009302241A patent/AU2009302241B2/en active Active
- 2009-10-08 JP JP2011531180A patent/JP2012505238A/ja not_active Withdrawn
- 2009-10-08 WO PCT/US2009/060058 patent/WO2010042759A2/en not_active Ceased
-
2012
- 2012-08-09 US US13/571,268 patent/US9186341B2/en active Active
-
2015
- 2015-02-23 JP JP2015032554A patent/JP6167123B2/ja active Active
- 2015-10-09 US US14/879,752 patent/US10478412B2/en active Active
-
2016
- 2016-07-28 HK HK16109028.9A patent/HK1220970A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8377990B2 (en) | Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders | |
| AU765038B2 (en) | Method for the treatment of insomnia | |
| CA2386297A1 (en) | Bicyclic amino acids as pharmaceutical agents | |
| RS55812B1 (sr) | Metilfenidatni prolekovi, procesi za njihovo dobijanje i njihova primena | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| JP2003506407A5 (enExample) | ||
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| RU2009145541A (ru) | Терапевтические соединения | |
| JP2005529840A5 (enExample) | ||
| JP2010526827A5 (enExample) | ||
| WO2007143185A3 (en) | Transdermal treatment of tendinopathy using glyceryl trinitrite | |
| HRP20230745T3 (hr) | Spojevi morfina | |
| AU2019268209B2 (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| BRPI0513337A (pt) | composição e processo para melhor biodisponibilidade e melhor aplicação ao cérebro de ácido 5,5-difenil barbitúrico | |
| JP6924184B2 (ja) | 疼痛の治療のための医薬組成物 | |
| KR20010071776A (ko) | 대상포진의 치료를 위한 ｇａｂａ 유사체 및항바이러스제를 포함하는 제약 조성물 | |
| AR071045A1 (es) | Estereo isomero de metil-( 2-hidroxi-5- (((2-(4-hidroxifenil)-1-metiletil) amino)etil)fenil)- carbamato, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo | |
| JP2019073507A5 (enExample) | ||
| WO2006133231A3 (en) | Treatment for neurodegenerative diseases | |
| MXPA00011509A (en) | Method for the treatment of insomnia | |
| RU2018137304A (ru) | Способы и композиции для доставки в цнс арилсульфатазы а | |
| RU2007136824A (ru) | Пролекарства амфетаминов с защитой от неправильного употребления | |
| JP2002520278A (ja) | Ｇａｂａ類縁体での腎仙痛の治療 |